Top 6 FDA 483s Stories of June 2013

topstories

The first part of the month was relatively quiet, but then things really start hitting the fan last week.  Here are some of the latest stories related to FDA 483s:

  1. Of course, the big story of the month is Ranbaxy.  FiercePharma reported that it may have been a 483 that explains why Ranbaxy did not get blockbuster Diovan to market. Ranbaxy declined to comment to FiercePharma “about whether a Form 483 had been issued for the plant”.  Our records show a few 483s issued to Ranbaxy, including the facility in question in northern India, at FDAzilla’s 483 searchable listing.  This story was widely reported (articles in Reuters, Business Standard, First Post, Money Control, Economic Times, and of course, FiercePharma)
  2. CNBC did a feature story/video of Intuitive Surgical on their key product line – the Da Vinci Surgical Robot. Basically, the FDA claims that Intuitive Surgical “broke procedure” by alerting customers before regulators about a minor “tip cover” issue. 2 things are interesting to me about this article: (a) 483s are mentioned in the 2nd sentence of the article and (b) there was a correction at the end of the article that reads, “This article has been revised to clarify the nature of the FDA’s letter to Intuitive Surgical.”  Very likely, this had to do with how the reporters read, initially understood and portrayed the FDA 483.  Looks like the Wall Street analysts understood how to put these 483s into context, though – 2 such analysts defended the company and re-iterated their “buy”/”outperform” rankings.
  3. 10 Takeaways from FDA’s Warning and Untitled Letters – great write-up by Alexander Gaffney. Alex and the rest of the RAPS team read all these 2013 letters to date and found some interesting themes. From a lack of toilet paper to equipment sizing/design to bugs, there is something for everyone.
  4. IntelliCell BioSciences proactively lets the world know that it received a FDA 483 – less than 2 weeks after the end of the inspection. Through a press release. A new wave of transparency or a random one-off? My guess is the latter.
  5. The FDA Enforcement Funnel by Oliver Yu @ Zymergi. Great visual of how it all works. Speaking of the funnel in action…
  6. FDA 483s lead to FDA Warning Letters. Take it to the bank. Note the different timeframes below, though most warning letters come 3-9 months after the 483s of note.

What hit your radar this month?

Other resources

Leave a Reply